Copyright
©The Author(s) 2016.
World J Gastroenterol. Dec 14, 2016; 22(46): 10124-10130
Published online Dec 14, 2016. doi: 10.3748/wjg.v22.i46.10124
Published online Dec 14, 2016. doi: 10.3748/wjg.v22.i46.10124
Table 3 Comparison of the gemcitabine/nab-paclitaxel and modified gemcitabine/nab-paclitaxel trials
| MPACT trial[10] (GNP) | Krishna et al[23] (Modified GNP) | ||
| Study design | Location | International | United States |
| Number of patients | 861 | 49 | |
| Dosing | Omission of Day 7 doses | ||
| Study design | Phase 3 | Retrospective | |
| Patient and tumor characteristics | Median age (yr) | 62 | 65 |
| Sex distribution | Male (57%) | Male (57%) | |
| Tumor stage | Metastatic | Metastatic | |
| Metastatic sites | Liver (85%) | Liver (57%) | |
| Lung (35%) | Lung (27%) | ||
| Peritoneum (4%) | Peritoneum (43%) | ||
| Tumor Location | Head (44%) | Head (51%) | |
| PFS (mo) | 5.5 | 4.8 | |
| OS (mo) | 8.5 | 11.1 | |
| Safety (Grade 3-4 toxicities) | Neutropenia | 38 | 10 |
| Thrombocytopenia | 13 | 4 | |
| Anemia | 13 | 15 | |
| Fatigue | 17 | 6 | |
| Peripheral neuropathy | 17 | 2 | |
| Diarrhea | 6 | 0 |
- Citation: Ghosn M, Ibrahim T, Assi T, El Rassy E, Kourie HR, Kattan J. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(46): 10124-10130
- URL: https://www.wjgnet.com/1007-9327/full/v22/i46/10124.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i46.10124